These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36454568)

  • 1. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
    Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
    JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
    Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y
    Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
    Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
    Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
    Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
    Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
    Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
    Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.
    Chen B; Chen W; Cheng Q; Zhang H; Wang B; Xu Y; Yang C; Cheng X; Wang R; Wang S; Cen P; Wang L; Dragomir MP; Zhu Y; Liu S; Xi M; Li Q; Chen B
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):1084-1095. PubMed ID: 38936631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
    Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
    Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
    Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
    Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
    Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
    Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
    Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
    Chen H; Zhou L; Yang Y; Yang L; Chen L
    Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma.
    Tan L; Xiao Z; Zhang H; Chen D; Feng Q; Zhou Z; Lv J; Liang J; Yin W
    Cancer Radiother; 2020 Feb; 24(1):21-27. PubMed ID: 32001131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae.
    Ma L; Luo GY; Ren YF; Qiu B; Yang H; Xie CX; Liu SR; Liu SL; Chen ZL; Li Q; Fu JH; Liu MZ; Hu YH; Ye WF; Liu H
    Chin J Cancer; 2017 Jan; 36(1):8. PubMed ID: 28077159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
    Song T; Du D; Zhang X; Fang M; Wu S
    Dis Esophagus; 2017 Sep; 30(9):1-10. PubMed ID: 28859362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes.
    Wang J; Wu Y; Zhang W; Chen Y; Liu Q; Jing S; Zhang J; Wu F; Wang J; Qiao X
    Radiat Oncol; 2023 Aug; 18(1):142. PubMed ID: 37641149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).
    Wang L; Wang X; Ren X; Han C; Xiao Z; Zhu S; Qiao X; Zhou Z; Shen W; Chen J; Pang Q; Zhang W; Zhao Y; Wang X; Sun X; Ge X; Zhang K; Hu M; Li G; Liu M; Wang Y
    Transl Cancer Res; 2021 Jun; 10(6):2932-2943. PubMed ID: 35116602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.